Spyridon Siafis,Virginia Chiocchia,Malcolm R Macleod,Charlotte Austin,Ava Homiar,Francesca Tinsdeall,Claire Friedrich,Fiona J Ramage,Jaycee Kennett,Nobuyuki Nomura,Olena Maksym,Grazia Rutigliano,Luke J Vano,Robert A McCutcheon,David Gilbert,Edoardo G Ostinelli,Claire Stansfield,Hossein Dehdarirad,Damian Omari Juma,Simonne Wright,Ouma Simple,Olufisayo Elugbadebo,Thomy Tonia,Ioannis Mantas,Oliver D Howes,Toshi A Furukawa,Lea Milligan,Carmen Moreno,Julian H Elliott,Janna Hastings,James Thomas,Susan Michie,Emily S Sena,Soraya Seedat,Matthias Egger,Jennifer Potts,Andrea Cipriani,Georgia Salanti,Stefan Leucht

Abstract:Background: Trace amine-associated receptor 1 (TAAR1) agonism shows promise for treating psychosis, prompting us to synthesise data from human and non-human studies. Methods: We co-produced a living systematic review of controlled studies examining TAAR1 agonists in individuals (with or without psychosis/schizophrenia) and relevant animal models. Two independent reviewers identified studies in multiple electronic databases (until 17.11.2023), extracted data, and assessed risk of bias. Primary outcomes were standardised mean differences (SMD) for overall symptoms in human studies and hyperlocomotion in animal models. We also examined adverse events and neurotransmitter signalling. We synthesised data with random-effects meta-analyses. Results: Nine randomised trials provided data for two TAAR1 agonists (ulotaront and ralmitaront), and 15 animal studies for 10 TAAR1 agonists. Ulotaront and ralmitaront demonstrated few differences compared to placebo in improving overall symptoms in adults with acute schizophrenia (N=4 studies, n=1291 participants; SMD=0.15, 95%CI: -0.05, 0.34), and ralmitaront was less efficacious than risperidone (N=1, n=156, SMD=-0.53, 95%CI: -0.86, -0.20). Large placebo response was observed in ulotaront phase-III trials. Limited evidence suggested a relatively benign side-effect profile for TAAR1 agonists, although nausea and sedation were common after a single dose of ulotaront. In animal studies, TAAR1 agonists improved hyperlocomotion compared to control (N=13 studies, k=41 experiments, SMD=1.01, 95%CI: 0.74, 1.27), but seemed less efficacious compared to dopamine D 2 receptor antagonists (N=4, k=7, SMD=-0.62, 95%CI: -1.32, 0.08). Limited human and animal data indicated that TAAR1 agonists may regulate presynaptic dopaminergic signalling. Conclusions: TAAR1 agonists may be less efficacious than dopamine D 2 receptor antagonists already licensed for schizophrenia. The results are preliminary due to the limited number of drugs examined, lack of longer-term data, publication bias, and assay sensitivity concerns in trials associated with large placebo response. Considering their unique mechanism of action, relatively benign side-effect profile and ongoing drug development, further research is warranted. Registration: PROSPERO-ID: CRD42023451628.

Discovery of potential TAAR1 agonist targeting neurological and psychiatric disorders: An in silico approach

Biological evaluation and in silico studies of novel compounds as potent TAAR1 agonists that could be used in schizophrenia treatment

Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies

Newly identified structures of trace-amine associated receptor-1 (TAAR1) will aid discovery of next generation neuropsychiatric drugs

TAAR1 as an emerging target for the treatment of psychiatric disorders

Structure-Based Design of Novel G-Protein-Coupled Receptor TAAR1 Agonists as Potential Antipsychotic Drug Candidates

Structural and signaling mechanisms of TAAR1 enabled preferential agonist design

AlphaFold accelerated discovery of psychotropic agonists targeting the trace amine-associated receptor 1

Novel 1-Amidino-4-Phenylpiperazines as Potent Agonists at Human TAAR1 Receptor: Rational Design, Synthesis, Biological Evaluation and Molecular Docking Studies

Discovery of Novel Trace Amine-Associated Receptor 5 (TAAR5) Antagonists Using a Deep Convolutional Neural Network

Trace amine associated receptor 1: predicted effects of single nucleotide variants on structure-function in geographically diverse populations

Ligand recognition and G-protein coupling of trace amine receptor TAAR1

Ligands of the trace amine-associated receptors (TAARs): A new class of anxiolytics

Discovery of a Novel Chemo-Type for TAAR1 Agonism via Molecular Modeling

Trace amine-associated receptor 1 (TAAR1) agonism for psychosis: a living systematic review and meta-analysis of human and non-human data

Molecular basis of human trace amine-associated receptor 1 activation

Discovery of Guanfacine as a Novel TAAR1 Agonist: A Combination Strategy through Molecular Modeling Studies and Biological Assays

[Research progress of trace amine-associated receptor 1 signaling pathways].

Artificial intelligence assisted identification of potential tau aggregation inhibitors: ligand- and structure-based virtual screening, in silico ADME, and molecular dynamics study

The versatile binding landscape of the TAAR1 pocket for LSD and other antipsychotic drug molecules

TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner